21-34892925-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 1P and 0B. PP3
This summary comes from the ClinGen Evidence Repository: NM_001754.5(RUNX1):c.97G>A (p.Asp33Asn) is a missense variant has a SpliceAI score ≥ 0.38 (Acceptor Loss: 0.68; Donor Loss: 0.76) and is predicted to impact splicing (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA10014629/MONDO:0011071/008
Frequency
Consequence
NM_001754.5 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RUNX1 | NM_001754.5 | c.97G>A | p.Asp33Asn | missense_variant, splice_region_variant | 3/9 | ENST00000675419.1 | NP_001745.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RUNX1 | ENST00000675419.1 | c.97G>A | p.Asp33Asn | missense_variant, splice_region_variant | 3/9 | NM_001754.5 | ENSP00000501943 | A1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.00000401 AC: 1AN: 249294Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134810
GnomAD4 exome AF: 0.00000214 AC: 3AN: 1399174Hom.: 0 Cov.: 25 AF XY: 0.00000143 AC XY: 1AN XY: 699648
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary thrombocytopenia and hematologic cancer predisposition syndrome Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen Myeloid Malignancy Variant Curation Expert Panel | Sep 25, 2024 | NM_001754.5(RUNX1):c.97G>A (p.Asp33Asn) is a missense variant has a SpliceAI score ≥ 0.38 (Acceptor Loss: 0.68; Donor Loss: 0.76) and is predicted to impact splicing (PP3). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: PP3. - |
Hereditary thrombocytopenia and hematological cancer predisposition syndrome associated with RUNX1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jun 02, 2023 | This variant is present in population databases (rs781761402, gnomAD 0.003%). This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 33 of the RUNX1 protein (p.Asp33Asn). This variant also falls at the last nucleotide of exon 3, which is part of the consensus splice site for this exon. This missense change has been observed in individual(s) with clinical features of thrombocytopenia (PMID: 32208489). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown this missense change is associated with skipping of exon 3, but one or more of the resulting mRNA isoform(s) may be naturally occurring (Invitae). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 409811). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at